Adaptive Immune Response to COVID-19 Vaccination
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Clinical Trials Related to mRNA-1273
Related studies linked through entity extraction aliases.
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
- Status
- COMPLETED
- Phase
- PHASE4
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
- Status
- COMPLETED
- Phase
- PHASE1
Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
- Status
- COMPLETED
- Phase
- PHASE1